Nexus Biopharma Inc. (fka NEXS)

[threewheeler]

Email not displaying correctly? View it in your browser.
Trade of the Year Logo (Image)
NEXS Seeks Nasdaq Listing in 2017

Valued members,
Our #1 trade of the year, Nexus Biopharma Inc. (NEXS) is off to an incredible start.

Since the beginning of September, NEXS has added over 78% to its market capitalization, creating significant value to shareholders and has turned into one of the fastest growing equities on the market today.

If you do not already hold NEXS in your portfolio, you are missing out on what may very well be one of the greatest trades of the decade—and that is not an exaggeration.

Remember, we know what a winner looks like. We have struck gold two years in a row, with COCP demonstrating over 500% returns in 2014/15 and XLIT providing over 900% to members in 2015/16. Those who paid attention to our alerts at the early stages walked away with considerable returns on the highs of both of those trades. View our track record here. http://www.otcmarkets.com/stock/COCP/chart
http://www.otcmarkets.com/stock/XLIT/chart guess they didnt check charts lately, LOL
If you have been struggling to make money in the markets recently, perhaps it is because you are not paying attention to the RIGHT companies. Do not hold on to losing situations. Cut your losses. Move capital into companies that are moving forward and are in strong up-trends.

With today's announcements, NEXS has—without a doubt—become the #1 equity to own moving into 2017.

If you have not yet already, read today's news from NEXS.

This is an incredible press release and an unbelievable early opportunity for our members to get involved with NEXS before the large funds begin to crowd-in and buy it up.


Some highlights of NEXS' accomplishments to date included:

Nexus (NEXS) Secured $2M of Institutional Funding

Nexus (NEXS) Appointed Jeffrey Pessin, Ph.D. to Advisory Board

Nexus (NEXS) Appointed Daniel Einhorn, M.D. to Advisory Board

Nexus (NEXS) Appointed Helen Stefanovic as Director of Regulatory Affairs

Nexus (NEXS) Filed International Patent to Extend Rights Internationally

Nexus (NEXS) Presented at the Royal Society of Chemistry Conference


Nexus Biopharma Inc. (NEXS) also clarified that its drug candidate will be orally administered. Most importantly, highlights of NEXS' plans going forward included:

Nexus (NEXS) Plans to Expand Into Multiple Indications Including:

- Treating Symptoms of Type II Diabetes
- Neurodegenerative Disease including Alzheimer's Disease
- Ageing, Another Blockbuster Opportunity

As if that wasn't enough, NEXS continued to surprise in its press release:

Nexus (NEXS) Seeks to Expand Its Pipeline With Synergistic Acquisitions

Nexus (NEXS) Meeting with the FDA by Q1 2017 for Pre-IND Regarding Phase 1

Nexus (NEXS) Will Commence Alzheimer's Studies in Q1 2017

Nexus (NEXS) Plans for Fast-Track Designation Meeting with FDA in Q3 2017

Nexus (NEXS) to Apply for Full Nasdaq Listing by Q3 2017


This was all contained in a single press release from the company. All we can say is... Wow!

NEXS is, hands down, the best company we have ever profiled.

Of all the companies out there, given today's news, NEXS most certainly deserves to be in the portfolio of a wise trader.

If you have any questions or do not understand why this is such a great trade, reply to this email. We are here to make sure you understand exactly how rare a situation like this truly is.

For those who may not be aware, NEXS is unlikely to remain sub-$4 for much longer. The minimum requirement to list on the Nasdaq is a $4 bid price. NEXS is planning to up-list by Q3 of 2017.

That pretty much all but guarantees NEXS will have to be $4+ by next September in order to gain its Nasdaq listing.

But that's a very conservative view.

With everything that NEXS has in store and the rate at which it is moving towards Phase-1 trials, once the IND filing goes through, NEXS is likely not going to be below $5 as large funds and firms rush to buy into the company that is developing the most promising weight-loss drug on the market today.

If you are not buying NEXS after reading this update, you have to seriously question your reasons for being in the markets at all.

Reward only comes to those who take the risk.

Those who risk it on NEXS are the only ones who will see the potential 1,000%+ returns here.

You have to make the leap and place your capital where you believe it will grow the greatest. What other companies do you have in your portfolio that will provide 500%+ returns in several months time? Do you have any that could go beyond and show 1,000%+? NEXS could.

Take time to study the facts here, this is one you want to dig into thoroughly and if you agree with our analysis, place your capital accordingly.

If you have not yet already, read the research report on NEXS below from industry professionals who have already given it a $9.73 target.
DOWNLOAD RESEARCH REPORT